A Study of Targeted Therapies for Patients With Recurrent Endometrial Cancer
Treatment
Phase 2 treatment study for recurrent endometrial cancer
Clinicaltrials.gov identifier:NCT04486352
Study Contact Information:
For additional information, please contact by phone at (617) 732-8727
or by email.
About the Study
This study is to test the safety and effectiveness of different kinds of with or without atezolizumab (or Tecentriq) in individuals with recurrent endometrial cancer. Participants will be placed into study groups based on their tumor.
This Study is Open To:
Women 18 years or older who:
- have a life expectancy of more than 12 weeks
- have recovered from effects of recent chemotherapy, radiation, or surgery
- have a tumor sample
- have recurrent endometrial cancer which has recurred after at least one but no more than two prior forms of therapy
This Study is NOT Open To:
Patients with:
- other invasive cancers within the last five years
- an active or history of autoimmune disease or immune deficiency
- active tuberculosis
- have significant heart disease
- have received a live vaccine in the last four weeks
- have had a severe infection within the last four weeks
- have had prior bone marrow transplant or antibiotic medication through the vein within the past four weeks
- More exclusion criteria found on clinicaltrials.gov
What the Study Involves
The study involves 6 groups:
Group 1:
Participants will receive Tecentriq intravenously (injected into the vein) on Day 1 of each cycle and bevacizumab (Avastin) intravenously every two weeks of the 28-day cycle.
Group 2:
Participants will receive Tecentriq intravenously (injected into the vein) on Day 1 of each cycle and Ipatasertib orally once daily for 21 days of the 28-day cycle.
Group 3:
Participants will receive Tecentriq intravenously (injected into the vein) on Day 1 of each cycle and (or ) orally once daily for every day of the 28-day cycle.
Group 4:
Participants will receive Tecentriq intravenously (injected into the vein) on Day 1 of each cycle and Trastuzumab emtansine (or Kadcyla) intravenously on Day 1 of each 21-day cycle.
Group 5:
Participants will receive Tecentriq intravenously (injected into the vein) on Day 1 of each cycle and Tiragolumab intravenously on Day 1 of each 28-day cycle.
Group 6:
Participants will receive Inavolisib and Lentrozole (or Femara) orally once daily for every day of the 28-day cycle.
Study Contact Information:
For additional information, please contact by phone at (617) 732-8727
or by email.
Locations:
Oklahoma
City: Oklahoma City RECRUITING
Facility: University of Oklahoma Health Stephenson Cancer Center
Contact Info:
Debra Richardson, MD
Treatment
Phase 2 treatment study for recurrent endometrial cancer
Clinicaltrials.gov identifier:NCT04486352
Study Contact Information:
For additional information, please contact by phone at (617) 732-8727
or by email.